MedTrace Logo

Evaluating Host and Viral Factors Among HIV Infected Former Commercial Blood Donors in Fuyang, Anhui Province, China

NCT00346762 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 186

Last updated 2014-05-19

No results posted yet for this study

Summary

HIV infected former commercial blood donors (FBDs) in Fuyang, Anhui Province, China were infected with HIV from a common-source exposure to contaminated blood. The purpose of this study is to examine the role of host and viral factors in HIV disease progression in this unique HIV infected population.

Conditions

  • HIV Infections

Interventions

BEHAVIORAL

Education

HIV prevention education and risk reduction counselig

Sponsors & Collaborators

  • Comprehensive International Program of Research on AIDS

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Yiming Shao, MD, PhD · National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC)

  • Jianqing Xu, MD, PhD · National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC)

  • Hui Xing, MD, MS · National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC)

  • Yuhua Ruan, PhD · National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC)

  • Jianjun Wang, MPH · Anhui Provincial Center for Disease Control and Prevention

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00346762 on ClinicalTrials.gov